Prohormone convertase 2 activity is increased in the hippocampus of Wfs1 knockout mice by Karin Tein et al.
ORIGINAL RESEARCH
published: 25 August 2015
doi: 10.3389/fnmol.2015.00045
Edited by:
Teresa Duda,
Salus University, USA
Reviewed by:
Bonnie L. Firestein,
Rutgers, The State University
of New Jersey, USA
Nicole Cyr,
Stonehill College, USA
*Correspondence:
Karin Tein,
Department of Physiology, Institute
of Biomedicine and Translational
Medicine, University of Tartu,
19 Ravila Street, 50411 Tartu, Estonia
karin.tein@gmail.com
Received: 01 July 2015
Accepted: 10 August 2015
Published: 25 August 2015
Citation:
Tein K, Kasvandik S, Kõks S, Vasar E
and Terasmaa A (2015) Prohormone
convertase 2 activity is increased
in the hippocampus of Wfs1 knockout
mice.
Front. Mol. Neurosci. 8:45.
doi: 10.3389/fnmol.2015.00045
Prohormone convertase 2 activity is
increased in the hippocampus of
Wfs1 knockout mice
Karin Tein1*, Sergo Kasvandik2, Sulev Kõks3,4, Eero Vasar1 and Anton Terasmaa1
1 Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia,
2 Proteomics core facility, Institute of Technology, University of Tartu, Tartu, Estonia, 3 Department of Pathophysiology,
Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia, 4 Department of Reproductive Biology,
Estonian University of Life Sciences, Tartu, Estonia
Background: Mutations in WFS1 gene cause Wolfram syndrome, which is a rare
autosomal recessive disorder, characterized by diabetes insipidus, diabetes mellitus,
optic nerve atrophy, and deafness. The WFS1 gene product wolframin is located in the
endoplasmic reticulum. Mice lacking this gene exhibit disturbances in the processing
and secretion of peptides, such as vasopressin and insulin. In the brain, high levels of
the wolframin protein have been observed in the hippocampus, amygdala, and limbic
structures. The aim of this study was to investigate the effect of Wfs1 knockout (KO)
on peptide processing in mouse hippocampus. A peptidomic approach was used to
characterize individual peptides in the hippocampus of wild-type and Wfs1 KO mice.
Results: We identified 126 peptides in hippocampal extracts and the levels of 10
peptides differed between Wfs1 KO and wild-type mice at P < 0.05. The peptide with
the largest alteration was little-LEN, which level was 25 times higher in the hippocampus
of Wfs1 KO mice compared to wild-type mice. Processing (cleavage) of little-LEN from
the Pcsk1n gene product proSAAS involves prohormone convertase 2 (PC2). Thus,
PC2 activity was measured in extracts prepared from the hippocampus of Wfs1 KO
mice. The activity of PC2 in Wfs1 mutant mice was significantly higher (149.9 ± 2.3%, p
< 0.0001, n = 8) than in wild-type mice (100.0 ± 7.0%, n = 8). However, Western blot
analysis showed that protein levels of 7B2, proPC2 and PC2 were same in both groups,
and so were gene expression levels.
Conclusion: Processing of proSAAS is altered in the hippocampus of Wfs1-KO mice,
which is caused by increased activity of PC2. Increased activity of PC2 in Wfs1 KO mice
is not caused by alteration in the levels of PC2 protein. Our results suggest a functional
link between Wfs1 and PC2. Thus, the detailed molecular mechanism of the role of Wfs1
in the regulation of PC2 activity needs further investigation.
Keywords: Wfs1, prohormone convertase 2, peptidomics, mass-spectrometry, proSAAS, 7B2, peptide processing
Introduction
Wolfram syndrome (WS) was ﬁrst described by Wolfram and Wagener (1938) and is a rare
autosomal recessive disorder characterized by diabetes insipidus (DI), diabetes mellitus (DM),
optic nerve atrophy (OA), and deafness (D) – DIDMOAD (Strom et al., 1998). WS is caused
by mutations in WFS1 gene, which is located in the fourth chromosome 4p16.1 region.
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Approximately 1% of the general population are heterozygous
carriers of WFS1 gene mutation and it has been found that these
carriers have increased risk for developing a psychiatric disease
(Swift et al., 1991). Though not all mutations inWFS1 gene cause
WS, carriers of WFS1 gene mutations have a 26 times higher risk
for psychiatric diseases such as depression and bipolar disorder
(Swift and Swift, 2000). Patients without WS, but exhibiting
bipolar disease, major depression, and schizophrenia have been
found to carry mutations inWFS1 gene (Strom et al., 1998; Evans
et al., 2000; Torres et al., 2001; Crawford et al., 2002).
WFS1 gene product is wolframin, a glycoprotein of 890 amino
acid residues and molecular weight of about 100 kDa (Strom
et al., 1998). Wolframin is mostly found in the brain, heart
and pancreatic insulin-producing β-cells. The highest levels of
expression in the brain are found in the hippocampus, amygdala,
allocortex and olfactory bulb (Takeda et al., 2001). On an
intracellular level, Wfs1 protein is located in the membrane of the
endoplasmic reticulum (ER), where it forms ∼400 kDa protein
complexes (Hofmann et al., 2003). Wolframin inﬂuences cellular
Ca2+ homeostasis and β-cell survival (Hofmann et al., 2003).
In addition, Wfs1 protein takes part in the regulation of the
ER-stress response (Rigoli et al., 2011).
Human studies have shown that peptide processing is
altered in patients with WS. Immunohistochemistry of the
autopsy samples reveal that processed vasopressin is absent in
the supraoptic and paraventricular nuclei of hypothalamus in
patients with WS (Gabreels et al., 1998). This was accompanied
by a lack of expression of prohormone convertase 2 (PC2) and
the chaperone secretogranin V (7B2) in this brain region of WS
patients (Gabreels et al., 1998). In addition to its localization
in the ER membrane, Wfs1 is also localized in the secretory
granules of beta-cells and participates in acidiﬁcation of these
granules (Hatanaka et al., 2011). Conversion of proinsulin
to insulin takes place in the secretory granules and is pH-
dependent (Hatanaka et al., 2011), thus, lack of Wfs1 results in
impaired insulin processing, which is manifested by an increased
proinsulin/insulin ratio (Hatanaka et al., 2011; Noormets et al.,
2011).
The role of Wfs1 in the regulation of insulin secretion and
survival of pancreatic beta-cells is a topic of ongoing research
and has attracted wide attention. On the other hand, there is
only one report on the role of WFS1 on the processing of
brain peptides (Gabreels et al., 1998). One of the regions in
the brain with the highest expression of Wfs1 is hippocampus
(Luuk et al., 2008). Thus, the aim of the present study was to
evaluate the processing of neuropeptides in this brain region
using a peptidomic approach. We have identiﬁed peptides in
which processing is altered in the hippocampus ofWfs1 KOmice,
and evaluated the activity of peptide processing enzymes that take
part in the processing of these peptides.
Materials and Methods
Wfs1 Knockout Mice
Test animals were male 129Wfs1 gene mutation mice
(129Wfs1KO) and control group animals were male wild-type
littermate (129WT) mice. Animals were kept in polypropylene
cages. The air temperature in the room was 21 ± 2◦C and light
cycle was 12 h light and 12 h dark. The light was switched on
at 7.00 am. Chow and drinking water was available ad libitum.
All of the procedures performed with animals were approved by
the Estonian National Board of Animal Experiments (No. 86,
28.08.2007) and were in accordance with the European Union
directive 86/609/EEC.
Generation of whole body Wfs1 knock out (KO) mouse
was described previously (Noormets et al., 2009). Brieﬂy, Wfs1
deﬁcient mice were generated by replacing most of the coding
region of the Wfs1 gene (exon8) with LacZ sequence. This
results in the deletion of the amino acids 360–890 of the Wfs1
protein and a fusion between remaining Wfs1 fragment and
LacZ. The oﬃcial designation of this strain is Wfs1tm1Koks
according to the Mouse Genome Database1. Mice with the
isogenic 129S6 background were used in this study. Genotyping
of the mice was performed by multiplex PCR for both alleles
using speciﬁc primers as described previously (Noormets et al.,
2009).
In general, eight Wfs1 KO and eight wild-type animals were
used for each kind of analysis, as diﬀerent tissue preparation was
needed for diﬀerent experiments. Altogether 96 mice were used
in this study.
Tissue Preparation
At the age of 3 months mice were sacriﬁced by cervical
dislocation. The brain was removed and the hippocampus
dissected out on a cold plate. Immediately thereafter tissue
samples were frozen in liquid nitrogen and kept at −80◦ C
until the analyses. Body weight of Wfs1 KO mice was smaller
compared to wild-type littermates (22.0 ± 0.7 g and 28.3 ± 0.5 g,
respectively; p< 0.0001; n = 30).
Peptide Extraction
Peptides were extracted from hippocampal tissue by a double
extraction protocol based on Frese et al. (2013). One hundred ﬁfty
microliter of acidiﬁed acetone (acetone/water/concentrated HCl
40:6:1) was added to the tissue sample. After microtip sonication,
samples were incubated for 1 h on ice. The samples were
then centrifuged for 25 min at 14,000 g (4◦C), the supernatant
was transferred to a new tube and neutralized by adding 1 M
NaOH (1:1 ratio to HCl). Acetone was evaporated using a
vacuum centrifuge. The pellet was washed with 0.25% acetic acid,
incubated on ice for an hour and collected by centrifugation for
25 min at 14,000 g (4◦C). The pellet and the supernatant were
combined and ﬁltered through a Millipore 10 kDA Amicon Ultra
YM-10 membrane for 30 min at 7,000 g. The ﬁltered peptide
extract was desalted using C18 StageTips (Rappsilber et al., 2007)
and reconstituted in 0.5% TFA.
Nano-LC/MS/MS Analysis
Injected peptides were separated on Ultimate 3000 RSLCyano
system (Dionex) using a C18 cartridge trap-column in backﬂush
conﬁguration and an in-house packed (3 μm C18 material, Dr
1http://www.informatics.jax.org
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MaischGmbh) analytical 50 cm × 75 μm emitter-column (New
Objective). Peptides were eluted at 200 nl/min with a 8–40%
B 90 min gradient (buﬀer B: 80% ACN + 0.1% FA, buﬀer A:
0.1% FA) to a Q Exactive (Thermo Fisher Scientiﬁc) tandem
mass spectrometer operating with a top-10 strategy and a cycle
time of 0.9 s. Brieﬂy, one 350–1400 m/z MS scan at a resolution
setting of R = 70,000 was followed by higher-energy collisional
dissociation fragmentation (normalized collision energy of 25) of
10 most intense ions (>+1 charge state) at R = 17,500. Dynamic
exclusion was limited to 40 s. An example of chromatogram and
mass spectrum are presented on Figure 1.
Raw Data Analysis
Raw data was processed with MaxQuant 1.4.0.8 software
package (Cox and Mann, 2008). Methionine oxidation and
protein N-terminal acetylation were set as variable modiﬁcations.
Search was performed against UniProt2 mouse neuropeptides
database (March 2014) using unspeciﬁc digestion rule. MS
and MS/MS mass errors were 4.5 and 20 ppm, respectively.
Only peptides minimally six amino acids long were accepted
and transfer of identiﬁcations between runs was allowed.
Peptide-spectrum match and protein FDR was kept below
1% using a target-decoy approach. All other parameters were
default.
Raw intensity values for each sample were summed up and
intensity value for each peptide in this sample was normalized for
the sum. Normalized values were analyzed using Student’s t-test.
P-value of less than 0.05 was considered as statistically signiﬁcant.
2www.uniprot.org
FIGURE 1 | An example of an extracted chromatogram (A) and MS/MS spectrum (B) of peptide LENPSPQAPA (little-LEN). The b- and y-series ions are
annotated on the MS/MS spectrum.
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Enzymatic Activity of PC2
The method is based on measuring the liberation of
aminocoumarin using a ﬂuorescence spectrophotometer
developed by Li et al. (2003). Aminocoumarin is cleaved
from the ﬂuorogenic substrate pGlu-Arg-Thr-Lys-Arg-AMC
via PC2-mediated cleavage. Hippocampus was weighed and
sonicated in 1 mL lysis buﬀer (0.1 M sodium acetate pH 5.5;
1% TritonX-100, 1 μM E64 (Sigma–Aldrich), 1 μg/ml pepstatin
(Sigma–Aldrich), and 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF). The volume of buﬀer was adjusted to give tissue
concentration 10 mg/ml. After centrifugation for 10 min at
10,000 g, supernatant was used for analysis of enzyme activity.
Samples and reagents were kept on ice at all times. Test tubes
were prepared for the measurement of enzymatic activity with
ﬁnal assay volume 200 μL, containing 50 μL supernatant, 0,1 M
sodium acetate (pH 5.5), and 2.5 mM calcium chloride and
0.25% TritonX-100. In order to test speciﬁcity, the synthetic
peptide (7B2-CT), which corresponds to the C-terminal portion
of human 7B2 (residues 155–185) was added to half of the
tubes at 30 μM ﬁnal concentration and tubes were incubated
for 15 min at 37◦C. Then the substrate p-Glu-Arg-Thr-Lys-
Arg-AMC (Sigma–Aldrich, ﬁnal concentration 0.2 mM) was
added to all tubes. Substrate was ﬁrst dissolved in DMSO;
the ﬁnal concentration of DMSO in the reaction mix was
2%. The reaction was 17 h long at 37◦C. The ﬂuorescence
of disengaged aminomethylcoumarin was measured using
ﬂuorescence – luminescence spectrophotometer (Luminescence
Spectophometer LS50B, Perkin Elmer) with excitation at 380 nm
and emission at 460 nm. Control samples without enzyme
and substrate were used as blanks. Speciﬁc PC2 activity was
calculated as diﬀerence of total activity of the reaction and
the activity in the presence of 7B2-CT peptide. Activity in
the presence of 7B2-CT was approximately 25–30% of total
activity.
Enzymatic Activity of Carboxypeptidase E
(CPE)
Themethod is based on the cleavage of the terminal arginine from
the substrate using a ﬂuorescence spectrophotometer developed
by Fricker et al. (1996). Hippocampus was dissected, weighed,
and homogenized in 2 ml lysis buﬀer (0.1 M NaAc, pH
5.5, 1 mM PMSF). For measuring carboxypeptidase E (CPE)
activity, 25 μL of the homogenate was added to 50 mM NaAc
buﬀer (pH 5.5), containing 0.01% Triton X100 and 200 μM
dansyl – Phe – Ala – Arg substrate in ﬁnal volume of 250 μL.
In addition, reaction mix contained either 1 mM CoCl2 or
1 μM guanidinoethylmercaptosuccinic acid (GEMSA). After
incubation at 37◦C for 30 – 60 min, 100 μL of 0.5 M HCl
was added to stop the reaction and 2 mL of chloroform was
added to extract dansyl – Phe – Ala. Tubes were mixed and
centrifuged at 500 × g for 2 min. The amount of product was
determined by measuring the ﬂuorescence (excitation 350 nm,
emission 500 nm) in the chloroform layer. CPE activity is deﬁned
as the diﬀerence between activity measured in the presence of
Co2+ (activates CPE) and in the presence of GEMSA (inhibits
CPE). Non- speciﬁc ﬂuorescence was measured in the absence of
the tissue extract. All measurements were done in duplicates.
Western Blot Analysis
Western Blot analysis for PC2 was done using NuPAGE
system (Life Technologies) according to manufacturer’s
guidelines.
Membranes with transferred proteins were blocked for 1 h
in 3% BSA in PBS. Thereafter, the membranes were incubated
with primary antibody overnight at 4◦C and were rinsed
six times in Milli-Q water. Membranes were incubated with
secondary antibody for 1 h at room temperature and washed
six times in Milli-Q water. Membranes were washed once for
20 min in PBS containing 0.1% Tween-20. Antibody detection
was performed using the LI-COR Odyssey CLx system (LI-
COR Biotechnologies). Images were converted to grayscale and
quantiﬁcation was performed using Image Studio Lite v 3.1.4
(LI-COR Biotechnologies). A commercial anti-PC2 antibody
(Thermo-Scientiﬁc, dilution 1:200) was used to detect active
isoform of PC2 (mass 69 kDa) and proPC2 (mass 72 kDa).
The secondary antibody was Alexa-790 conjugated donkey anti
rabbit (Jackson ImmunoResearch Laboratories, Inc., dilution
1:40,000).
RNA Isolation, cDNA Synthesis and
Quantitative Real-Time PCR
Samples were put on ice and homogenized with 200 μL Trizol
(Trizol R© Reagent, Invitrogen, USA) when the tissue was slightly
thawed. Samples were incubated at room temperature for 5 min,
chloroform was added and tubes were shaken for 15 sec. Samples
were again incubated for 2 min at room temperature. Samples
were centrifuged for 15 min, 12,000 g at 4◦C. The upper water
phase was removed to a new 1.5 mL tube and isopropanol in
half of the Trizol volume was added. Tubes were turned to mix
carefully and incubated for 10 min at room temperature. Samples
were centrifuged for 10 min, 12,000 g at 4◦C. Supernatant was
taken away carefully and 1 mL of ice-cold 75% EtOH was added
to RNA. Tubes were centrifuged for 10 min, 10,000 g, at 4◦C.
Supernatant was removed carefully and tubes were left to dry
until all the EtOH was evaporated. 250 μL MQ was added and
RNA was frozen at −80◦C. Before freezing the samples, RNA
quality control was performed using Nanodrop. The 260/230 and
260/280 ratios were around 2.00.
One microgram of total RNA of each sample with random
hexamers (Applied Biosystems) and SuperScriptTM III Reverse
Transcriptase (Invitrogen, USA) were used for the ﬁrst strand
cDNA synthesis. Thermal cycling was performed using 7900HT
Fast Real- time PCR system (Applied Biosystems) at 95◦C
for 10 min, then 40 cycles at 95◦C for 15 sec and 60◦C
for 1 min. Probes were designed from exon–exon junctions
eliminating the possibility of genomic DNA contamination.
Hprt1 was used as housekeeper gene as it is a reliable reference
gene.
For RT-PCR, each sample was performed in four parallel
reactions. The experiment was repeated two times and a negative
control was used. The ampliﬁcation curves of the housekeeping
gene, PC2 and 7B2 were similar and the amount for each
transcript was calculated using standard curve of cycle threshold
for serial dilutions of the sample and normalized to Hprt1
expression.
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Radioimmunoassay (RIA)
Acid extracts (0.1 M HCl) were prepared from tissues by
homogenizing in 200 (pituitary) or 1 ml (hippocampus) of
ice-cold 0.1 M HCl. The samples were centrifuged at 15,000 g
for 15 min and the clear supernatant was lyophilized. Samples
were reconstituted in 0.5 ml of RIA buﬀer (−0.1 M sodium
phosphate, pH 7.4, with 50 mM sodium chloride, and 0.1% BSA
and azide), shaken for 30 min at room temperature, centrifuged,
and 100 μL duplicates measured for 7B2 using a sensitive RIA
employing an antiserum to residues 23–39 (Zhu and Lindberg,
1995).
Protein Measurement
Micro BCATM Protein Assay Kit (Thermo Scientiﬁc) was used for
the protein measurement and the analysis was done according to
the manufacturer’s protocol.
Statistical Analysis
Unpaired two-tailed Student’s t-test was used to compare
experimental groups. A P-value of less than 0.05 was
considered as statistically signiﬁcant. Data are presented as
mean ± SEM.
Results
Peptidomic Study
One hundred and twenty-six individual peptides with sequence
length of 8–24 amino acids were identiﬁed (Supplementary
Table S1). The molecular weight of identiﬁed peptides was in the
range from 757 to 2817 Da. Most of the identiﬁed peptides were
derived from 11 precursor sequences: galanin; orexin/hypocretin;
neuropeptide Y; proprotein convertase subtilisin/kexin type 1
inhibitor; preprodynorphin; proenkephalin-A; melanin-
concentrating hormone; prepronociceptin; neuroendocrine
protein 7B2; substance P and teneurin-1.
The levels of 10 peptides were found to be diﬀerent in Wfs1
KO versus wild-type mice (Table 1). The peptide with the biggest
fold change was little-LEN, a peptide derived from proSAAS.
Little-LEN is cleaved from proSAAS in a PC2 dependent manner
(Figure 2). As the level of little-LEN was 25 times higher in
FIGURE 2 | Primary sequence and processing sites of proSAAS.
Prohormone convertase 2 (PC2) participates in the cleavage of proSAAS at
residue 209 (arrow 4). The amount of the underlined peptide little-LEN is 25
times higher in the hippocampus of the Wfs1 KO mice as compared to their
wild-type littermates, which prompted the measurement of PC2 activity in
Wfs1 KO mice.
Wfs1 KO mice, we decided to measure the activity of PC2 in the
hippocampus of these mice.
Prohormone Convertase 2 Activity
Measurement
The activity of PC2 in the hippocampus of Wfs1 KO mice was
measured using a ﬂuorogenic substrate coupled with a speciﬁc
PC2 inhibitor. PC2 activity was signiﬁcantly higher in Wfs1
KO mice compared to wild-type mice (Figure 3A), which is in
accordance with the elevated little-LEN peptide levels in Wfs1
KO mice. PC2 participates in the cleavage of proSAAS at residue
209 (Sayah et al., 2001), thus producing little-LEN (Figure 2,
arrow 4).
As the activity of PC2 was signiﬁcantly higher in Wfs1 KO
animals, we measured the protein and mRNA levels of PC2 as
well to see whether the increased activity was due to elevated
mRNA or protein levels. 7B2 performs a dual function for
PC2: while the C-terminal part of 7B2 inhibits active PC2, the
remainder of the protein is needed to obtain active PC2 from
proPC2. Therefore, we also measured mRNA and protein levels
of 7B2.
TABLE 1 | The list of identified peptides from mice hippocampus whose level was dependent on the Wfs1 genotype (n = 6 per genotype).
Precursor gene name Peptide sequence Mass, Da Measurement error,
ppm
Peptide name Fold change Wfs1
KO/wild-type
p-value
Pcsk1n LENPSPQAPA 1022.503 −0.42 Little-LEN 25.19 0.0016
Penk YGGFMRSL 929.4429 −1.08 Met-enkephalin-
Arg-Gly-Leu
4.98 0.0065
LRGNKSIS 873.5032 −0.82 3.05 0.0069
Pcsk1n SLSAASAPLVETSTPL 1542.814 −0.15 Little-SAAS 1–16 0.69 0.011
DSDSEAYPEDSERR 1654.671 0.38 1.47 0.018
Pcsk1n SVDQDLGPEVPPENVLGAL 1947.979 −0.94 PEN-19 0.32 0.027
Pcsk1n SVDQDLGPEVPPENVLGALLRV 2316.233 −4.33 PEN 0.22 0.036
Pcsk1n SVDQDLGPEVPPENVLGA 1834.895 −0.84 PEN-18 0.56 0.040
Scg5 VEYPAHQAMNLVGPQSIEG 2038.978 −1.46 0.52 0.041
Penk PEWWMDYQ 1153.454 −0.62 Peptide-E 0.40 0.05
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FIGURE 3 | Prohormone convertase 2 in the hippocampus of Wfs1 mice.
(A) PC2 activity is higher in Wfs1 KO mice (149.9 ± 2.3%, n = 8,
∗∗∗p < 0.0001) than wild-type mice (100.0 ± 7.0%, n = 8). The activity of PC2
is shown as percentage of the wild-type group. PC2 activity in the hippocampus
of wild-type mice was 12.1 pmol/mg protein/min. Activity in the presence of
7B2-CT was approximately 25–30% of total activity. (B) Radioimmunoassay
(RIA) for measuring 7B2 protein level. Immunoreactivity was slightly higher in
wild-type mice (109.5 ± 6.0, n = 8) than in Wfs1 KO mice (97,1 ± 2,9, n = 8),
though these results are not significantly different. (C,D) mRNA levels of PC2
and 7B2, respectively, were measured with qPCR. PC2 mRNA expression levels
were similar in both groups (5.63 ± 0.53, n = 7 in wild-type mice and
5.50 ± 0.39, n = 8 in Wfs1 KO mice). 7B2 mRNA expression levels were similar
in both groups (1.39 ± 0.08, n = 8 in wild- type mice and 1.32 ± 0.08, n = 8 in
Wfs1 KO mice). (E) Protein levels of PC2 were similar in Wfs1 KO mice
(0.77 ± 0.14, n = 8, p = 0.27) and in wild-type mice (1.00 ± 0.10, n = 8).
(F) Carboxypeptidase E (CPE) activity was similar in Wfs1 KO mice
(106.5 ± 2.7%, N = 8) and wild-type mice (100.0 ± 4.01%, n = 8). Student’s
t-test was used for statistical analysis.
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PC2 and 7B2 Protein and mRNA Levels
Prohormone convertase 2 and 7B2 protein levels were measured
with Western blot analysis. There was no diﬀerence in PC2
protein levels between the groups (Figure 3E). As Western
blotting is not sensitive enough to measure 7B2 protein levels,
RIA was used for that purpose. There was no diﬀerence in
7B2 protein levels in Wfs1 KO and wild-type mice (Figure 3B).
There was also no diﬀerence in mRNA levels of PC2 and 7B2
(Figures 3C,D).
In sum, we found no signiﬁcant diﬀerence in the protein and
mRNA levels of both PC2 and 7B2, yet the activity of PC2 was
signiﬁcantly higher and so were the levels of peptide little-LEN, a
product thought to be generated by PC2.
CPE Activity
To obtain active neuropeptides and peptide hormones, two
sets of enzymes are needed. First, PCs, like PC2, cleave the
precursor at speciﬁc sites to generate peptides with C-terminal
basic residues; these intermediates are then cut by CPE to remove
basic residues (Fricker et al., 1996). Therefore we measured the
activity levels of CPE with ﬂuorescence spectrophotometry. We
found no signiﬁcant diﬀerence of CPE activity levels in the
hippocampus of Wfs1 KO (106.5 ± 2.7%, N = 8) and wild-type
mice (100.0 ± 4.01%, N = 8, Figure 3F).
Discussion
The Wfs1 protein is highly expressed in pancreatic beta-cells,
and the role of Wfs1 in the processing and secretion of insulin
is relatively well studied (Hatanaka et al., 2011). Wfs1 is also
expressed in the brain, and the highest levels of this protein
are found in the limbic structures, amygdala, second layer of
the cortex and hippocampus (Luuk et al., 2008). Heterozygous
mutations in WFS1 increase the risk of psychiatric disorders
without causing WS (Swift et al., 1998; Swift and Swift, 2000,
2005), although this view has been challenged (Kato et al., 2003;
Martorell et al., 2003). Nevertheless, a recent meta-analysis of
genome-wide expression studies revealed WFS1 mRNA to be
signiﬁcantly elevated in the prefrontal cortex of patients with
bipolar disorder (Seifuddin et al., 2013). Therefore, Wfs1 seems
to be important in the regulation of brain function in addition
to its well-known role in neurodegeneration. To the best of
our knowledge, there is only one study connecting WFS1 with
peptide processing in the brain, in which lack of vasopressin
processing was revealed in the hypothalamus of WS patients
(Gabreels et al., 1998). Therefore, the aim of this study was to
evaluate the peptide proﬁle in the hippocampus of Wfs1 KOmice
using a peptidomic approach. The hippocampus was chosen as
this region shows high expression levels of Wfs1 (Luuk et al.,
2008).
In this study we used mice of the age of 3 months. At this
age Wfs1 KO animals already display characteristic phenotype.
The growth of Wfs1 KO mice stops at age of 2 months while
wild-type mice continue to grow, thus, body weight of Wfs1
KO animals is smaller than body weight of wild-type animals
at the age of 3 months (Luuk et al., 2009; Punapart et al.,
2014). Wfs1 KO mice used in this study are also smaller than
their wild-type littermates, indicating functional consequence of
Wfs1 invalidation. The basal blood glucose levels are similar
for both genotypes even at the age of 6 months (Terasmaa
et al., 2011), while Wfs1 KO animals display glucose intolerance
already at the age of 2–3 months (Luuk et al., 2009). Although
glucose tolerance in Wfs1 KO mice was not measured in this
study, we can presume that 3 months old Wfs1 KO mice used
in this study display glucose intolerance that reﬂect a lack of
Wfs1 function. WS is a severe disorder that is characterized
by optic atrophy, deafness, and diabetes (Rigoli et al., 2011).
Glucose intolerance of Wfs1 KO mice seem to correlate well
with the human condition. However, other characteristics of
WS may take longer time to manifest in mice and therefore,
direct comparison of mice with patients suﬀering fromWS is not
straightforward.
Amass-spectrometric approach to identify individual peptides
was used in this study. 126 individual peptides were identiﬁed and
levels of 10 peptides were statistically signiﬁcantly dependent on
the Wfs1 genotype.
The peptide with the largest increase was little-LEN, a product
of cleavage of proSAAS (the Pcsk1n gene product). The closely
related peptide big-LEN was recently found to be an agonist
for hypothalamic G protein-coupled receptor GPR171, which
plays a role in central regulation of feeding and metabolism
(Gomes et al., 2013). However, little-LEN has no activity at
GPR171 (Gomes et al., 2013). Little-LEN is cleaved from pro-
SAAS in a PC2- and furin-dependent manner (Sayah et al., 2001)
(Figure 2), we therefore evaluated the activity of PC2 in Wfs1
KO mice. Our results indicate that PC2 activity is upregulated
in the hippocampus of Wfs1 KO mice. This is in contrast with
a previous report, where lack of vasopressin processing was
associated with the absence of PC2- and 7B2-immunoreactivity in
the paraventricular nucleus of WS patients (Gabreels et al., 1998).
Also, the protein level of PC2 was not changed in the pancreatic
beta-cells of Wfs1-null mice (Hatanaka et al., 2011). Thus, PC2
might be diﬀerentially regulated by Wfs1 in diﬀerent cell types.
In this study we found no alterations in protein or mRNA levels
of PC2 and its chaperone 7B2 in the hippocampus of Wfs1 KO
mice. As the activity of PC2 is increased, there is a possibility
that Wfs1 regulates enzymatic activity of PC2 via a completely
diﬀerent mechanism rather than simply regulating its expression
level.
Prohormone convertase 2 is found in neuroendocrine
cells, which contain a regulatory secretory pathway. These
cells are capable of processing diﬀerent prohormones like
provasopressin, proinsulin, proenkephalin, prosomatostatin,
pro-TRH, proopiomelanocortin (POMC) and many others
(Benjannet et al., 1991; Breslin et al., 1993; Brakch et al., 1995;
Friedman et al., 1995). The main task of PC2 is proteolytic
processing of neuropeptide and peptide hormone precursors.
The PCs are widely expressed in the brain cortex, hippocampus,
and hypothalamus (Schafer et al., 1993). PC2 itself is activated
via proteolytic cleavage; immature 75-kDa proPC2 is cut to
yield active 68-kDa PC2. Such cleavage is not necessary for PC2
secretion, but is needed for its activation (Taylor et al., 1997).
PC2 diﬀers from all other PCs in its requirement for interaction
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FIGURE 4 | A scheme illustrating possible mechanisms of regulation of
PC2 by Wfs1. ProPC2 with its chaperon 7B2 are transported into endoplasmic
reticulum (ER), where they form a complex, which exits the ER without PC2
propeptide cleavage. Thereafter 7B2- proPC2 complex enters Golgi complex,
where 7B2 is internally cleaved into 21 kDa amino terminal part (7B2-AT) and 31
amino acids long carboxy-terminal part. Then 7B2-AT-proPC2 complex is
transported into maturing secretory granules. In the maturing secretory granules
PC2 propeptide is cleaved to an active PC2. Wfs1 protein is localized in the
membrane of ER and also secretory granules, where it regulates Ca++ levels
and pH. In turn, pH and Ca++ are known to regulate activity of PC2. In addition,
lack of Wfs1 function leads to increased ER stress, which can alter proper
folding of proPC2 and 7B2 in the ER.
with the neuroendocrine-speciﬁc protein 7B2 to generate active
PC2 (Zhu and Lindberg, 1995). Interaction between proPC2 and
7B2 is complex and occurs in diﬀerent cellular compartments
(Figure 4; Muller and Lindberg, 1999). The 7B2 protein was
ﬁrst isolated from the pituitary gland in the 1980s (Martens,
1988). It is found in the central nervous system and endocrine
tissues (Seidah et al., 1983). 7B2 is synthesized as 185 amino
acid precursor protein and during passage through the secretory
pathway it is cut into two fragments – amino-terminal (21-kDa)
and carboxyl-terminal part (7B2-CT; Laurent et al., 2002). The
amino-terminal part is necessary to activate proPC2 (Zhu and
Lindberg, 1995); and at the same time, the 7B2-CT peptide is a
highly selective PC2 activity inhibitor (van Horssen et al., 1995).
However, we found no alterations in mRNA and protein levels of
7B2 in the hippocampus of Wfs1 KO mice (Figure 3D).
The activity of PC2 is further regulated in several diﬀerent
ways. Acidiﬁcation of secretory granules is required for proper
functioning of PC2 (Hatanaka et al., 2011) and acidiﬁcation of
secretory granules in pancreatic beta-cells is Wfs1 dependent
(Hatanaka et al., 2011). However, the eﬀect of Wfs1 invalidation
on acidiﬁcation of secretory granules in the brain is unknown.
In addition to the pH, maturation of PC2 is also regulated by
calcium levels (Shennan et al., 1995) and Wfs1 is well known to
be involved in regulation of intracellular calcium (Osman et al.,
2003). Also, the activity of 7B2 is regulated via its phosphorylation
(Lee et al., 2006). We suggest that Wfs1 can regulate activity of
PC2 via any of these mechanisms in the brain. However, the
precise mechanism of involvement of Wfs1 in the regulation of
PC2 activity in the brain is unknown and needs further attention.
As all of the proposed mechanisms of regulation of PC2 are on
the intracellular level, it is also necessary to investigate whether
PC2 and Wfs1 are co-expressed in the same cells in the brain.
The peptide whose level showed the next largest Wfs1-
dependent change was Met-enkephalin-Arg-Gly-Leu, a product
of proenkephalin cleavage (Table 1). This peptide showed
strongly reduced levels in the hypothalamus of PC2-KO mice
(Pan et al., 2006). In this study, we found that the level of
Met-enkephalin-Arg-Gly-Leu was almost ﬁve times higher in
the hippocampus of Wfs1 KO mice, thus, pointing to a higher
activity of PC2. A higher level of this peptide further supports the
increased activity of PC2 in the hippocampus of Wfs1 KO mice.
Conclusion
We identiﬁed 126 individual peptide fragments in mouse
hippocampal extracts. Analysis of the relative abundance of these
peptides revealed alterations in the processing of proSAAS and
proenkephalin in the hippocampus of Wfs1 KO mice, which is
most likely caused by an increase in the activity of PC2. The
increased activity of PC2 in Wfs1 KO mice is not a result of
increased levels of the PC2 protein or its chaperone 7B2. Thus,
the role of Wfs1 in the regulation of PC2 activity requires further
investigation.
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